Our track record
Since 2019, we have completed 70+ biotechnology strategy reviews, undertaken 20+ sell-side transactions & 40+ buy-side projects.
Whilst much of our work in the M&A space is confidential, a selection of our completed projects are listed below.
We support a broad set of transactions, including:
- Management-led buyouts
- Disposals (assets and stock)
- Specialist Commercial Due Diligence (CDD)
We have a proprietary database of sellers globally, covering manufacturers, distributors and hybrid resellers.
|European life science distribution companies
|Veterinary diagnostics distributors
|IVD Reagents and raw materials
|Life science reagent distributors
|Manufactures of antibodies, kits and proteins
|IVD reagent and raw materials
6th November, London, UK – Life Science Logistics firm Percorso Life Sciences today announced their acquisition by Parel Bio, LLC. Pivotal Scientific Limited (PSL) exclusively…
Abcore approached Pivotal Scientific to exclusively manage the sale of the company to Fortis Life Sciences, trusting our previous support and recognizing our skills in M&A…
The Chromocyte Journey from startup to maturity to acquisition: Pivotal Scientific has assisted Chromocyte throughout its business lifecycle. We are delighted to have supported it…
Pivotal Scientific are pleased to announce their involvement in Arlington Scientific, Inc. acquiring the non-mammalian blocking buffer product line from Clark McDermith, former owner of East…
Pivotal Scientific Limited supported Atlas Antibodies in their decision making on the purchase of Evitria by undertaking commercial due diligence and providing expert advisory services. Atlas Antibodies wanted to make…
Pivotal Scientific Limited (PSL) is pleased to announce its assistance in the sale of Hungarian based Biotechnology company SCICONS to Nordic MUbio based in the…
Pivotal Scientific are delighted to have advised the shareholders of Absolute Antibody, Ltd. (UK) and its sister company Kerafast on their sale to LSBio (USA)….